NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines
The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...
COVID-19
CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
Hybio’s COVID-19 Nasal Spray HY3000 Gets FDA Clinical Trial Approval
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving tacit clinical trial approval from...
Huahai Pharma Raises Funds for Digital Manufacturing and API Platform
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD...
Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials
China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...
Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...
JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course
Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...
Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales
Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...
Pfizer Reports Record Revenues as COVID-19 Sales Soar; 2023 Guidance Amid Market Shifts
US-based Pfizer Inc. (NYSE: PFE) reported its Q4 2022 financial results, highlighting an all-time high...
Junshi Biosciences Partners with Huahai for Production of COVID-19 Drug VV116
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a production and supply agreement between...
Beijing HSA Sets Price for Hainan Simcere’s COVID-19 Therapy SIM0417
Beijing’s municipal Healthcare Security Administration (HSA) bureau has released details of the initial quote and...
NMPA Approves Two China-Developed COVID-19 Small-Molecule Therapies
The National Medical Products Administration (NMPA) has issued conditional marketing approvals to two novel, China-discovered...
Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...
CNBG-Virogin’s Omicron-Targeted mRNA Vaccine Approved for Clinical Trials
CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical...
Hansoh’s HS-10517 Greenlit for COVID-19 Clinical Study by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its oral nucleoside analog drug...
Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...
Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...